Minjuvi Monjuvi News Today : Breaking News, Live Updates & Top Stories | Vimarsana

– Total revenues of $881 million in the first quarter – Jakafi® net product revenues of $572 million in Q1 24, total paid patients increased +5% Y/Y; reiterating full year 2024 guidance of.

United kingdomHong kongUnited statesRetifanlimab zynyzPonatinib iclusigRuxolitinib jakaviCapmatinib tabrectaMinjuvi monjuviPemigatinib pemazyreBaricitinib olumiantTafasitamab monjuviDrug administrationMacrogenics incAmerican academy of dermatologyPharmaceuticals incUs food drug administration